VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.

Angiogenesis is crucial for the progression of colorectal carcinomas in which the bioavailability of Vascular Endothelial Growth Factor (VEGF) plays a major role. VEGF bioavailability is regulated by proteolytic release or cleavage. In colorectal cancer patients, we observed a significant correlation between circulating VEGF and tumour tissue Matrix Metalloproteinase-9 (MMP-9) levels but not with MMP-2. Therefore, we evaluated the role of MMP-9 in regulating VEGF bioavailability and subsequent angiogenesis in 3-dimensional human cell culture models. MMP-9 treatment released VEGF dose-dependently from HT29 colon carcinoma spheroids, comparable to heparitinase, a known mediator of VEGF release. Conditioned medium from human neutrophils, containing high amounts of active MMP-9, released VEGF comparable to recombinant MMP-9, in contrast to myofibroblast medium. MMP-9 treated spheroids showed decreased extracellular levels of heparan sulphates, required for VEGF binding to the matrix, whereas the levels in the medium were increased. Western blot analysis revealed that VEGF(165) is the major isoform released by MMP-9 treatment. In vitro experiments indicated that MMP-9 is not capable to cleave VEGF(165) into smaller isoforms, like plasmin does. These data suggested that MMP-9 mediates release rather than the cleavage of larger VEGF isoforms. Medium from MMP-9 treated HT29 spheroids induced endothelial cell sprouting in an angiogenesis assay, comparable to the effect of recombinant VEGF(165). Anti-VEGF antibody treatment resulted in a strongly reduced number of sprouts. In conclusion, we have shown that neutrophil-derived MMP-9 is able to release biologically active VEGF(165) from the ECM of colon cancer cells by the cleavage of heparan sulphates.

[1]  J. Quigley,et al.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis , 2007, Proceedings of the National Academy of Sciences.

[2]  G. Taraboletti,et al.  Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. , 2006, Neoplasia.

[3]  Taiji Ito,et al.  The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells , 2007, Oncogene.

[4]  Eleonora Marrazzo,et al.  Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy , 2005, Molecular Cancer Therapeutics.

[5]  F. Bayard,et al.  Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.

[6]  C. Davies,et al.  Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenografts, multicellular spheroids, and monolayer cultures. , 1997, Anticancer research.

[7]  J. Breau,et al.  Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature , 2005 .

[8]  J. Plouët,et al.  Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. , 1998, Biology of the cell.

[9]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[10]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[11]  G. Taraboletti,et al.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.

[12]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[13]  H. Verspaget,et al.  Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. , 2007, European journal of cancer.

[14]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[15]  X. Bai,et al.  Developmental changes in heparan sulfate expression: in situ detection with mAbs , 1992, The Journal of cell biology.

[16]  Qi Dong,et al.  Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. , 2003, World journal of gastroenterology.

[17]  Christopher J. Robinson,et al.  VEGF165-binding Sites within Heparan Sulfate Encompass Two Highly Sulfated Domains and Can Be Liberated by K5 Lyase* , 2006, Journal of Biological Chemistry.

[18]  Terri L. McKay,et al.  A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. , 2006, Microvascular research.

[19]  M A Moses,et al.  Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[21]  R. Benamouzig,et al.  Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature , 2005, British Journal of Cancer.

[22]  H. Verspaget,et al.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[24]  M. Neurath,et al.  Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy , 2005, Expert review of anticancer therapy.

[25]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[26]  Lynne T. Haber.  Mode of Action , 2005 .

[27]  H. Nielsen,et al.  Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma , 2000 .

[28]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[29]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[30]  S. Chakrabarti,et al.  Regulation of matrix metalloproteinase‐9 (MMP‐9) in TNF‐stimulated neutrophils: novel pathways for tertiary granule release , 2006, Journal of leukocyte biology.

[31]  B. Cauwe,et al.  The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases , 2007, Critical reviews in biochemistry and molecular biology.

[32]  Wilhelm Bloch,et al.  Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. , 2006, The American journal of pathology.

[33]  T. V. van Berkel,et al.  Efficient degradation-aided selection of protease inhibitors by phage display. , 2007, Biochemical and biophysical research communications.

[34]  M. Klagsbrun,et al.  Vascular endothelial growth factor and its receptors. , 1996, Cytokine & growth factor reviews.

[35]  I. Pecker,et al.  The FASEB Journal express article 10.1096/fj.00-0895fje. Published online May 29, 2001. , 2022 .

[36]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[37]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[38]  Cornelis F. M. Sier,et al.  Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients , 2007, British Journal of Cancer.

[39]  P. Quax,et al.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. , 1991, Gastroenterology.

[40]  Cornelis F. M. Sier,et al.  Beta‐glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation , 2004, International journal of cancer.

[41]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  Anton Dormer,et al.  Evolutionary analysis of human vascular endothelial growth factor, angiopoietin, and tyrosine endothelial kinase involved in angiogenesis and immunity , 2005, Silico Biol..

[43]  A. Strongin,et al.  Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. , 2002, Cancer research.

[44]  H. Hurwitz,et al.  Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. , 2005, Seminars in oncology.